Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

242.79 -3.06 (-1.24%)
Streaming Delayed Price Updated: 10:52 AM EDT, Aug 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
3 Profitable Stocks with Questionable Fundamentals
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
Topics Economy
Jazz Pharmaceuticals (NASDAQ:JAZZ): A Decent Value Opportunity ↗
Via Chartmill
News headline image
Jazz Pharmaceuticals (JAZZ) Q2 2026 Earnings Call Transcript ↗
Revenue hit $1.2 billion with oncology sales surging and Xywav demand accelerating. 
Via The Motley Fool
Topics Earnings
News headline image
5 Revealing Analyst Questions From Jazz Pharmaceuticals’s Q2 Earnings Call
Jazz Pharmaceuticals delivered a positive Q2, with a strong 16% year-over-year revenue increase driven primarily by its oncology and rare disease portfolios.... 
Via StockStory
Topics Earnings
Cannabis Theme's Hidden Strength: Established Players Outshining Pure Plays ↗
Via Chartmill
Topics Cannabis
Cannabis Theme Rally Powered by Profitability, Not Pure-Play Speculation ↗
Via Chartmill
Topics Cannabis
Cannabis Stocks Split into Two Camps: Profitable Operators vs. High-Growth Speculation ↗
Via Chartmill
Topics Cannabis
News headline image
Jazz Pharmaceuticals Q2 Earnings Call Highlights ↗
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported second-quarter 2026 revenue of $1.21 billion, up 16% from a year earlier, as growth across its sleep, epilepsy and oncology portfolios drove record quarterly... 
Via MarketBeat
Topics Cannabis Earnings
News headline image
Jazz Pharmaceuticals (NASDAQ:JAZZ) Reports Bullish Q2 CY2026, Guides for Strong Full-Year Sales
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 15.5% year on year t... 
Via StockStory
News headline image
Jazz Pharmaceuticals (JAZZ) Q2 Earnings: What To Expect
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings tomorrow after market hours. Here’s what to look for. Jazz Pharmaceuticals be... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Value Stocks with Open Questions
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t... 
Via StockStory
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) Presents a Decent Value Opportunity with Strong Valuation and Growth Potential ↗
Via Chartmill
Jazz Pharmaceuticals (NASDAQ:JAZZ) Flashes Perfect Minervini Trend Template Score with 116% Annual Surge ↗
Via Chartmill
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surges 3.7% After-Hours on Q1 2026 Revenue and EPS Beat ↗
Via Chartmill
News headline image
3 Overrated Stocks Walking a Fine Line
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab... 
Via StockStory
News headline image
Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It Looks ↗
The long-term thesis remains largely unchanged. 
Via The Motley Fool
News headline image
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Jazz Pharmaceuticals (JAZZ): Buy, Sell, or Hold Post Q1 Earnings?
Jazz Pharmaceuticals has had an impressive run over the past six months as its shares have beaten the S&P 500 by 28.7%. The stock now trades at $232.44, mark... 
Via StockStory
Topics Stocks
News headline image
Pharmaceuticals Stocks Q1 Recap: Benchmarking Jazz Pharmaceuticals (NASDAQ:JAZZ)
Let’s dig into the relative performance of Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers as we unravel the now-completed Q1 pharmaceuticals earnings seaso... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Unpopular Stocks We Find Risky
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
Via StockStory
Topics Credit Cards
News headline image
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗
Ultragenyx develops therapies for rare genetic diseases, with a portfolio spanning approved biologics and a pipeline of gene therapies. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Healthcare Stocks We Think Twice About
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory de... 
Via StockStory
News headline image
3 Mid-Cap Stocks We’re Skeptical Of
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe... 
Via StockStory
News headline image
Is Marriott Stock a Buy After GMT Capital Initiated a Position Worth Over $66 Million? ↗
This hospitality firm runs 120+ upscale vacation properties worldwide, leveraging exclusive brands and recurring fee-based revenue. 
Via The Motley Fool
News headline image
Jazz Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst Questions
Jazz Pharmaceuticals delivered a first quarter that was met with a positive response from the market, driven largely by strong commercial execution across it... 
Via StockStory
Topics Earnings
News headline image
Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why
What Happened? Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 5.4% in the afternoon session after the company reported strong first-qu... 
Via StockStory
News headline image
JAZZ Q1 Deep Dive: Oncology and Neuroscience Drive Double-Digit Revenue Growth, Eyes on Upcoming Approvals
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 19.1% year on year ... 
Via StockStory
News headline image
Jazz (JAZZ) Q1 2026 Earnings Call Transcript ↗
Jazz (JAZZ) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q1 CY2026 Sales
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) announced better-than-expected revenue in Q1 CY2026, with sales up 19.1% year on year to $1.07 billion. ... 
Via StockStory
News headline image
Jazz Pharmaceuticals (JAZZ) Q1 Earnings Report Preview: What To Look For
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results this Tuesday after market hours. Here’s what you need to know. Jazz Pharmaceut... 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.